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Abstract: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO)
synthesis, and its structural isomer symmetric dimethylarginine (SDMA) are uremic toxins
accumulating in chronic kidney disease (CKD) patients. The objective of this study was to develop
and validate a robust UPLC-MS/MS method for the simultaneous determination of ADMA and
SDMA in human serum. Chromatographic separation after butyl ester derivatization was achieved
on an Acquity UPLC BEH C18 column, followed by tandem mass spectrometric detection. After
validation, the applicability of the method was evaluated by the analysis of serum samples from
10 healthy controls and 77 CKD patients on hemodialysis (CKD5HD). Both ADMA (0.84 ˘ 0.19 µM
vs. 0.52 ˘ 0.07 µM) and SDMA concentrations (2.06 ˘ 0.82 µM vs. 0.59 ˘ 0.13 µM) were significantly
(p < 0.001) elevated in CKD5HD patients compared to healthy controls. In general, low degrees of
protein binding were found for both ADMA and SDMA. In addition, an established commercially
available ELISA kit was utilized on the same samples (n = 87) to compare values obtained both
with ELISA and UPLC-MS/MS. Regression analysis between these two methods was significant
(p < 0.0001) but moderate for both ADMA (R = 0.78) and SDMA (R = 0.72).
Keywords: asymmetric dimethylarginine; symmetric dimethylarginine; UPLC-MS/MS; ELISA;
chronic kidney disease
1. Introduction
Chronic kidney disease (CKD) is a worldwide public health problem with cardiovascular disease
as the most important and often fatal complication [1,2]. A myriad of toxic solutes, normally cleared
by the kidneys, among which asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine
(SDMA), accumulate in the body of CKD patients [3]. Both originate from proteolysis of methylated
proteins [4]. Arginine residues within proteins can be post-translationally methylated by a class of
enzymes, named protein arginine methyltransferases. Proteolysis of proteins containing methylated
arginine releases free methylarginines into the cytosol. Once released, ADMA acts as an endogenous
inhibitor of nitric oxide synthase by competing with L-arginine as the substrate [5]. Elevated
plasma ADMA levels have been associated with endothelial dysfunction [5,6], which is an essential
contributing element to vascular disease, and were found in patients with various risk factors for
atherosclerosis such as in CKD [7,8]. Plasma ADMA levels may predict the progression of renal injury
in patients with early-stage CKD [9,10], and are an independent risk factor for cardiovascular disease
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and all-cause mortality in different populations, such as patients with coronary artery disease [11,12]
and patients with end stage renal disease [13,14]. SDMA, a structural isomer of ADMA, has long
been considered biologically inactive [4,5]. Biologic activity was however at first suggested by the
finding of a dose-responsive inhibition of NO synthesis by a mechanism different from that elicited
by ADMA [15]. Subsequently, SDMA was shown to play a prominent role in leukocyte activation
by enhancing generation of radical oxygen species, which is attributable to increased calcium influx
via store-operated Ca2+ channels [16] and to activation of nuclear factor-κB resulting in cytokine
production [17]. In addition, SDMA was proposed as biomarker for renal function outperforming
creatinine-based equations for determining estimated glomerular filtration rate [18,19].
It has been suggested that the removal of ADMA in standard hemodialysis is completely
hampered, eliciting the hypothesis that the compounds are protein bound [20]. Other studies confirmed
that removal of dimethylarginines is lower than would be expected with regard to their molecular
weight [21,22]. However, in the latter studies the decrease in ADMA was obviously more substantial
than in the one by Kielstein et al., [20]. Hence, investigation of the protein-binding of ADMA and
SDMA is essential to shed light on these inconsistent results.
Since ADMA shows a very narrow range of normal concentrations, even a small increase in its
concentration might be linked to cardiovascular risk. Therefore, high analytical precision is of extreme
importance to discriminate between normal and slightly elevated concentrations. Current methods
for determination of ADMA and SDMA in biofluids include gas chromatography coupled with mass
spectrometry (GC-MS) [23,24], high performance liquid chromatography (HPLC) with fluorescence
detection (HPLC-FLD) after derivatization [25–32], HPLC with mass spectrometric detection (LC-MS
and LC-MS/MS) underivatized [13,33–41] or after derivatization [42–46], and capillary electrophoresis
coupled with ultraviolet (CE-UV) [47] or with mass-spectrometric detection (CE-MS) [48]. In
addition, an enzyme-linked immunosorbent assay (ELISA) has been developed [49] and several
comparisons between this assay and chromatographic methods have been described for ADMA [49–55].
Some comparisons suggest that the enzyme-linked immunosorbent assay (ELISA) assay for ADMA
suffers from matrix effects producing concentration-dependent positive bias compared with other
methods [50–52]. Moreover, some discrepancies seem to exist between the reported method
comparisons. For SDMA no method comparisons have been described yet.
In this study, the primary aim was to develop and validate a robust ultra (high) performance
liquid chromatography (U(H)PLC)-MS/MS method for the simultaneous determination of ADMA and
SDMA in human serum. Secondly, we investigated the protein binding of ADMA and SDMA in serum.
Finally, the UPLC-MS/MS data were compared with an established ELISA for both ADMA and SDMA.
The UPLC-MS/MS method with the MRM detection was chosen because of its power to measure
specific compounds in a very accurate way with a minimum of interferences and its possibility to
perform high throughput analysis. The latter method was compared to ELISA because this method
can be easily introduced in a research setting.
2. Results
To promote retention on the Acquity UPLC BEH C18 column and to improve sensitivity, the
dimethylarginines were derivatized to their butyl ester analogues. This derivatization was based on
the method described by Schwedhelm et al., [46], strengthening the selectivity of the method. Different
mobile phase compositions were compared to achieve retention, separation, symmetric peak shapes,
method robustness and fast analysis. Ammonium acetate buffer solution (5 mM, pH 4.3) was mixed
with 15% methanol (containing 0.1% acetic acid) as initial mobile phase. Detection was performed
by tandem mass spectrometry operated in multiple reaction monitoring (MRM) mode, which is
characterized by its sensitivity and selectivity and therefore widely implemented in bioanalysis.
ADMA and SDMA exhibit the same protonated molecular ion with mass-to-charge ratio (m/z) of 259
and have their most intense mass transition in common (259Ñ 70). Next to this transition they have
unique mass transitions, which have lower intensity. ADMA fragments by loss of 45 (corresponding
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to dimethylamine) and SDMA by loss of 31 (corresponding to methylamine). Although ADMA and
SDMA were almost baseline separated and it was therefore not absolutely necessary to distinguish them
by their different fragmentation pattern, we chose to monitor these unique transitions because of the
unequivocal selectivity towards the parent compounds. The sensitivity for the dimethylarginines was
further optimized by adjustment of the cone and collision energy potentials (Table 1). Representative
MRM chromatograms obtained from a CKD5HD patient are depicted in Figure 1. No interferences
from other endogenous substances were apparent.
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Figure  1. Representative  chromatograms  obtained  simultaneously  via  the UPLC‐MS/MS method 
from  a CKD patient on hemodialysis  for ADMA  (mass  transition  259/214)  (A)  and SDMA  (mass 
transition 259/228) (B) and for the internal standard (mass transition 266/221) (C). 
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Figure 1. Representative chromatograms obtained simultaneously via the UPLC-MS/MS method from
a CKD patient on hemodialysis for ADMA (mass transition 259/214) (A) and SDMA (mass transition
259/228) (B) and for the internal standard (mass transition 266/221) (C).
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Table 1. Detection settings for the investigated compounds.
Compound Structure tR (min)
Transition (after
Derivatization) Cone (V)
Collision
Energy (eV)
ADMA
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After optimization, the figures of merit of the method were established. The results of the accuracy,
within- and between-day precision, recovery, limit of detection (LOD) and limit of quantification (LOQ)
tests are summarized in Table 2. The LOD and the LOQ were below the lowest calibration point
of the seven-point calibration curves (i.e., below 0.1 µM). Good linearity (r2 ě 0.99) was observed
for both dimethylarginines using a least square fit. Isotopically labeled ADMA served as internal
standard for both ADMA and SDMA. The deviation of the mean measured concentration of the
quality control (QC) samples from the theoretical concentration was below 12.35%. Within- and
between-day precision were below 3.48% and 10.93%, respectively. Recoveries were high and more
importantly reproducible. The effect of the matrix on signal intensity was below 15% for all 6 serum
samples. The occurrence of a significant matrix ffect could therefore be excluded. Moreover, the use
of the isotopically labeled internal standard, the gradient to 100% mobile phase A (0.1% acetic acid in
methanol), and the additional isopropanol wash after every 15 injections were all measures reducing
the risk for such effect.
Table 2. Figures of merit.
Uremic
Toxin
LOD
(nM)
LOQ
(nM)
QC Concentration
Added (µM)
Accuracy
(%)
Within-Day
Precision (%)
Between-Day
Precision (%)
Recovery
(%)
ADMA 7.9 23.7
0.25 ´9.65 2.00 7.79 100.5 ˘ 3.3
0.49 ´8.14 3.48 6.13 102.2 ˘ 3.2
0.99 ´4.87 2.56 5.25 98.7 ˘ 2.5
SDMA 6.4 19.2
0.25 ´12.35 3.34 9.92 96.2 ˘ 4.8
1.24 ´6.83 2.31 10.93 94.6 ˘ 5.5
3.71 11.69 1.93 8.61 97.4 ˘ 4.1
LOD: limit of detection; LOQ: limit of quantification; QC: quality control samples.
Patient and control characteristics are displayed in Table 3. Hemodialysis patients were
routinely dialyzed for 245 ˘ 18 min, with a blood flow of 321 ˘ 37 mL/min (QB range
220–350 mL/min) and QD = 500 mL/min in hemodialysis mode with high flux dialyzer, or in
postdilution hemodiafiltration mode.
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Table 3. Characteristics of controls and patients.
Characteristics Healthy Controls CKD5HD Patients
Number 10 77
Female 6 32
Age 61.4 ˘ 11.2 69.6 ˘ 12.4
Body weight (kg) 69.2 ˘ 15.9 71.2 ˘ 16.3
Dialysis vintage (months) n.a. 39.2 ˘ 23.1
Diabetes 0 31
CKD5HD: Chronic kidney disease stage 5 on hemodialyis; n.a.: not applicable.
Figure 2 displays the dimethylarginine serum concentrations determined by UPLC-MS/MS in
healthy controls and CKD5HD patients. ADMA and SDMA concentrations are both significantly
elevated in CKD patients compared to healthy controls (p < 0.001). For ADMA, we found a mean
concentration of 0.52 ˘ 0.07 µM in healthy controls and 0.84 ˘ 0.19 µM in CKD5HD patients. For
SDMA, mean normal concentration is 0.59 ˘ 0.13 µM and mean concentration in CKD5HD patients
is 2.06 ˘ 0.82 µM. The control values are within the previously reported ranges for ADMA [50] and
slightly higher for SDMA [27,35]. Our reported concentrations for CKD patients are also consistent
with published values [27,56].
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Figure 2. ADMA (a) and SDMA (b) serum concentrations determined by UPLC-MS/MS in healthy
controls (n = 10) and CKD5HD patients (n = 77), * p < 0.001 versus healthy.
In general, low degrees of protein binding were found for both ADMA and SDMA. Protein binding
of ADMA is 6.53%˘ 4.93% in healthy controls and 4.01%˘ 2.90% in hemodialysis patients. For SDMA
protein binding is 12.02% ˘ 8.73% in healthy controls and 10.36% ˘ 9.74% in hemodialysis patients.
It was, however, not possible to determine the phenomenon accurately as most of the concentration
differences were smaller than the error margins of the method. An unpaired t-test showed that the total
concentrations were significantly higher (p < 0.0001) than the free concentrations in all conditions. A
significant increase in ADMA and SDMA was also seen in hemodialysis patients versus healthy controls
for both total and free concentrations. For SDMA, however, quite high interindividual variability in
protein binding was encountered. Basic compounds such as dimethylarginines might preferentially
bind to alpha1-acid glycoprotein (AAG) [57], an acute phase protein that is often elevated in CKD [58].
In order to obtain more information on the interindividual differences, the correlation between protein
binding and AAG concentration was investigated. However, no correlation between these variables
was found. Nevertheless, we can conclude that ADMA and SDMA are only minimally protein bound
in contrast to what is described by Kielstein et al., [20] and that therefore, it is more likely that the
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removal of ADMA in standard dialysis is hampered because of complex kinetics and distribution
rather than of protein binding as recently suggested by Schepers et al., and Sitar et al., [59,60].
Next to the developed UPLC-MS/MS method, a commercially available ELISA assay was
performed in parallel to determine ADMA and SDMA in the same 87 serum samples. This assay
provided mean normal concentrations of 0.49 ˘ 0.06 µM for ADMA and 0.62 ˘ 0.09 µM for SDMA.
Mean concentrations of 0.97 ˘ 0.23 µM for ADMA and 2.09 ˘ 0.59 µM for SDMA were found in
CKD5HD patients. In a previous study by our group [17], we already found in a cross-sectional
analysis of 142 patients in consecutive stages of CKD, using the same ELISA assays, that both ADMA
and SDMA increase with decrease in renal function.
UPLC-MS/MS and ELISA results showed only moderate correlation, with R = 0.78 for ADMA
and R = 0.72 for SDMA. In literature, different method comparisons have been described for ADMA
determination only. Schulze et al., reported for the first time on the ELISA assay for ADMA [49]. To
assess the analytical performance of the assay, ELISA was compared with a GC-MS and LC-MS/MS
method [49]. Good correlations were found for both GC-MS (R = 0.991, p < 0.0001) and LC-MS/MS
(R = 0.984, p < 0.0001). However, in three out of the nine samples submitted to the GC-MS method,
serum was spiked with ADMA concentrations exceeding the concentrations found in human serum
of CKD patients. In spite of the good correlation, an overestimation of ~20% was observed for the
serum ADMA concentrations determined by ELISA compared with LC-MS/MS. Subsequently, several
independent groups also compared their methods with the commercially available ELISA for ADMA.
Valtonen et al., found no correlation between serum ADMA concentrations determined by HPLC-FLD
(orthophtaldialdehyde (OPA)-derivatization) and the ELISA assay [55]. However, Schulze et al.,
signaled that the ELISA kit controls were outside the given range in two out of three ELISA kits [53].
Martens-Lobenhoffer et al., found considerable disagreement in the Bland-Altman plot between LC-MS
(OPA-derivatization) and ELISA for ADMA concentrations in plasma from healthy and diseased
individuals [51]. The ELISA assay appeared to overestimate the ADMA concentrations by a factor
of about two. The matrix dependence of the ELISA was suggested as cause of this overestimation.
Široká et al., found good correlation (R = 0.944, p < 0.0001) for plasma ADMA concentrations between
HPLC-FLD (OPA-derivatization) and the ELISA assay [54]. However, the ELISA assay provided about
two-fold higher ADMA concentrations than HPLC-FLD. Horowitz and Heresztyn found a linear
relationship with an R2 = 0.69 between ADMA concentrations (serum and plasma) determined by
HPLC-FLD (AccQ-Fluor™ derivatization, Waters, Milford, MA, USA) and ELISA [50]. However, the
difference between the two methods increased with increasing ADMA concentration, as was also
the case in the study by Martens-Lobenhoffer et al., [54]. Pecchini et al., compared plasma ADMA
concentrations determined by LC-MS and ELISA (R = 0.69) and again an increasingly pronounced
overestimation in ADMA levels by ELISA was found with increasing ADMA concentration [52]. After
checking normality and linearity of the residuals, linear regression analysis of the concentrations
measured in the present study was performed. As shown in the left panel of Figure 3 we could
demonstrate that, although moderate, a significant linear relationship (p < 0.0001) exists between
ELISA and the UPLC-MS/MS method for both ADMA (R = 0.78) and SDMA (R = 0.72). Based on
Bland Altman graphs the two methods tend to show dissimilarity with increasing concentrations. In
general, ELISA tends to overestimate ADMA concentrations (Figure 3, right panel). Moreover, the
difference between the two methods tends to increase with increasing ADMA concentration, which is
in agreement with previous findings. For SDMA no method comparisons have been described yet and
no reference frame is therefore available. From the Bland-Altman plot a slightly inversed trend seems
visible for SDMA, but no fixed bias could be shown.
By comparison, the new proposed UPLC-MS/MS method, which allows simultaneous
determination of both arginine derivatives in the CKD range while ensuring robustness due to the
chromatographic separation, is shown to be efficient and applicable in CKD research. The observed
and reported discrepancies related to the ELISA assay warrant further study.
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3. Conclusions
In conclusion, a robust UPLC-MS/MS has been developed and validated for the simultaneous
determination of ADMA and SDMA in serum. The method has been applied to analyze serum from
healthy controls and CKD patients on hemodialysis. A significant increase in serum concentrations was
found in hemodialysis patients. Protein binding of both ADMA and SDMA has been investigated and
low protein binding was suggested, therefore in the future only total concentration of both compounds
needs to be considered. Accuracy and precision testing confirm the effectiveness of the UPLC-MS/MS
methodology. Comparison between the developed UPLC-MS/MS method and the commercially
available ELISA showed a moderate correlation, this needs to be taken into account when considering
absolute concentrations. When estimating changes in concentrations e.g., during dialysis therapy, both
methods are applicable.
4. Materials and Methods
Merck (Darmstadt, Germany). The int rnal standard 2,3,3,4,4 5,5-d7-ADMA:HCl:H2O (d7-ADMA,
98%) was purchased from Camb idge Isotope Labora ries, Inc. (Andover, MA, USA). Methanol and
wa er, b th LC-MS g ade, were purchased from Biosolve (Valkenswaard, The Netherlands). Acetic
acid was obtained from Panreac (Barc lona, Spai ). Ammonium acetate was purchased from Fluka
(Bornem, Belgium). 1-Butanol was obtained from Merck (Darms dt, Germany) and hydrochloric
acid from Fluka (Bornem, Belgium). ELISA kits were purchased from DLD Diagnostika GmbH
(Hambur , Germany).
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4.2. UPLC-MS/MS Assay
4.2.1. Instrumentation
The Waters UPLC-MS/MS system comprised an Acquity UPLC System and a Quattro Micro
triple quadrupole mass spectrometer (Milford, MA, USA). Separation was performed on an Acquity
UPLC BEH C18 column (1.7 µm, 2.1 mm ˆ 100 mm) with an Acquity UPLC BEH C18 VanGuard
precolumn (1.7 µm, 2.1 mm ˆ 5 mm). The mobile phase consisted of 0.1% acetic acid in methanol
(mobile phase A) and 0.1% acetic acid in 5 mM ammonium acetate (mobile phase B, pH 4.3). A gradient
elution at a flow of 0.25 mL/min was performed with an initial composition of 15% A, which was held
for 3.5 min, followed by an increase in 0.01 min to 100% A (for 1.5 min) and finally a re-equilibration
(5 min). The total run time was 10 min. The column was flushed with isopropanol every 15 runs to
remove phospholipids which can be a significant source of imprecision in quantitative analyses [61].
The column temperature and the autosampler temperature were kept at 21 ˝C and 8 ˝C, respectively.
Mass spectral ionization, fragmentation, and acquisition parameters were optimized on the tandem
quadrupole mass spectrometer using electrospray ionization (ESI) in the positive mode (Table 1). The
ion source temperature and the desolvation temperature were maintained at 120 and 350 ˝C. Nitrogen
was used as nebulizer and desolvation gas. The desolvation gas flow was set at 650 L/h and the cone
gas flow was 10 L/h. Capillary voltage was 3260 V. The collision gas (argon, purity 99.999%) was set
at 3.44 ˆ 10´1 Torr. Quantification was performed in the multiple reaction monitoring (MRM) mode
with dwell and interscan delay times of 0.2 and 0.1 s, respectively. Data were acquired and processed
using Masslynx software (version 4.0, Waters, Milford, MA, USA).
4.2.2. Preparation of Stock Solutions, Calibration Standards and Quality Control (QC) Samples
Stock solutions of ADMA (1.24 mM), SDMA (1.24 mM) and d7-ADMA (4.78 mM) were prepared
in water for HPLC (Merck). An internal standard solution containing 2.39 µM d7-ADMA was obtained
from the stock solution by dilution with H2O. This solution was further used for spiking all calibration
solutes and the samples such that they contained a final concentration of 0.60 µM d7-ADMA, at injection.
Calibration curve standards were prepared at 0.1, 0.25, 0.49, 0.74, 0.99, 1.24 and 1.48 µM for ADMA
and at 0.1, 0.25, 0.49, 1.24, 2.47, 3.71 and 4.94 µM for SDMA. Low, medium, and high-concentration
quality-control (QC) samples were prepared by combining three samples of normal serum, selected
because of their low levels of endogenous uremic toxins, and spiking them with appropriate amounts
of dimethylarginines, taking into account the endogenous baseline level. The low, medium, and high
QC samples were spiked with, respectively, 0.25, 0.49 and 0.99 µM ADMA and 0.25, 1.24 and 3.71 µM
SDMA. All calibration standards and QC samples were freshly prepared on the day of analysis and
were run in triplicate. All stock solutions were stored at ´20 ˝C and were stable at these conditions.
4.2.3. Sample Preparation
The sample preparation procedure described by Meert et al., was slightly adapted [62]. Blood
samples from healthy controls and CKD5HD patients allowed to clot and were subsequently
centrifuged. Serum was collected, frozen and stored at ´80 ˝C. Serum samples were thawed at
room temperature and vortex mixed to ensure homogeneity. Subsequently, 40 µL of internal standard
solution (2.39 µM of d7-ADMA) was added to 160 µL of serum, vortex mixed and 600 µL of water
was added. To determine the total concentration, serum samples were first deproteinized by heat
denaturation. To this end, samples were heated for 30 min at 90 ˝C. After heating, the samples
were placed on ice for 10 min. All serum samples were then ultrafiltered using Millipore Centrifree
ultrafiltration devices (MWCO 30,000 Da, Millipore, Billerica, MA, USA) at 1469ˆ g for 25 min. To
determine the free fraction, serum samples were filtered through Millipore Centrifree ultrafiltration
devices prior to heating. Subsequently, 600 µL of ultrafiltrate was dried under nitrogen at room
temperature. ADMA, SDMA and the internal standard were analyzed as their butyl ester derivatives.
Derivatization step was performed by dissolving the dried extract in 500 µL of a freshly prepared
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1 M HCl in 1-butanol solution. After 2 min vortexing, the solution was kept at 70 ˝C for 20 min. The
solvent was subsequently removed by evaporation under nitrogen. The derivatized samples were
reconstituted in 120 µL of the initial mobile phase and were transferred to an autosampler vial (glass
insert P/N WAT094171). Afterwards, 20 µL was injected on the column. Samples were prepared on
the day of analysis.
4.2.4. Validation
The tested validation parameters were selectivity, LOD, LOQ, linearity, accuracy, precision,
recovery, and matrix effects. The limits of detection were determined according to the EPA
recommended procedure [63]. A standard solution containing each dimethylarginine at the estimated
signal to noise (S/N) of 10 was injected seven times, and the standard deviations of the peak areas
(and of the corresponding concentrations) were calculated. The limits of detection were calculated
by multiplying the standard deviations by three. The limit of quantification was calculated as three
times the LOD. Seven point calibration curves were generated with aforementioned concentrations
(Section 4.2.2). Quantification was carried out by internal standard calibration with d7-ADMA as
internal standard for both ADMA and SDMA. The accuracy and precision of the method were
evaluated by the analysis of spiked samples at three QC levels (n = 5). Accuracy was defined as the
difference between the calculated and the specified amount for the selected compound and expressed
as a percentage. Precision was obtained as the percentage relative standard deviation (% RSD) for a
selected compound and level. The relative recovery (%) was determined by comparing the peak area
ratios of ADMA and SDMA in normal serum samples spiked before heat denaturation to the peak
area ratios of normal serum spiked after ultrafiltration, respectively. To evaluate matrix effects, we
spiked water and six different serum samples at the low QC level and compared the areas obtained in
water with those of the spiked serum samples.
4.2.5. Application to Biological Samples
The described method was applied to serum samples from healthy controls (n = 10) and from
CKD patients on hemodialysis (CKD5HD, n = 77). In order to establish protein binding, both total
(T) and free (F) concentrations were determined for the healthy control group and for 20 randomly
selected CKD5HD patients. The degree of protein binding was calculated as follows: (T ´ F)/T ˆ 100.
The present study was approved on 10 June 2010 by the local Ethics Committee (Belgian registration
number: (B67020107926), Ghent University Hospital, Ghent, Belgium), and performed in accordance
to the Declaration of Helsinki. Written informed consent was obtained from all participants.
4.3. ELISA Assay
Two established competitive ELISA’s were used for measuring ADMA and SDMA according
to manufacturer’s guidelines. Briefly, serum samples were acylated before adding to the microtiter
plate. Overnight, acylated ADMA or SDMA competes with the solid phase bound ADMA or SDMA
for a fixed number of rabbit anti-ADMA or anti-SDMA antiserum binding sites. After equilibration,
antibody bound to the solid phase ADMA or SDMA is detected by the reaction of anti-rabbit peroxidase
and the substrate TMB (3,31,5,51-Tetramethylbenzidine). Samples were analyzed using the EL808 Ultra
Microplate Reader from Bio-Tek Instruments (Winooski, VT, USA) at 450 nm (reference wavelength of
650 nm) using the KC4V3.0 Analysis Software (Bio-Tek®Instruments, INC., Winooski, VT, USA). The
amount of antibody measured is inversely proportional to the ADMA or SDMA concentration.
4.4. Nephelometric Assay
Alpha1-acid glycoprotein (AAG), an acute phase protein with a MW of 43 kDa, was determined
by nephelometry on a Siemens Dade Behring Nephelometer (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany).
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4.5. Statistical Analysis
Normality was checked and results are expressed as means ˘ standard deviations. Statistics
were performed using GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) via
correlation analysis, unpaired t-test and Bland-Altman plots. A p-value of <0.05 was considered
as statistically significant.
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Abbreviations
The following abbreviations are used in this manuscript:
ADMA asymmetric dimethylarginine
SDMA symmetric dimethylarginine
CKD chronic kidney disease
CKD5HD CKD patients on dialysis
HPLC high performance liquid chromatography
UPLC Ultra performance liquid chromatography
ELISA enzyme-linked immunosorbent assay
GC gas chromatography
MS mass spectrometry
FLD fluorence detection
CE capillary electrophoresis
UV ultraviolet
m/z mass-to-charge ratio
LOD limit of detection
LOQ limit of quantification
QC quality control
AAG a1-acid glycoprotein
OPA orthophtaldialdehyde
S/N signal to noise
RSD relative standard deviation
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